Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moertel, C. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moertel, C. G.

Journal of Clinical Oncology, Vol 1, 727-740, Copyright © 1983 by American Society of Clinical Oncology


ARTICLES

Treatment of the carcinoid tumor and the malignant carcinoid syndrome

CG Moertel

Certainly in treatment of the carcinoid tumor surgery has a well- established curative and palliative potential. The primary challenge is a knowledgable marriage between stage of disease and aggressiveness of operative procedure. Nonsurgical treatment of the malignant disease per se has thus far not produced optimum results and, in the opinion of this author, should still be confined to a clinical research setting. It would seem very doubtful, however, that the more mundane types of trials, empirically testing drug after drug and arbitrarily concocted drug combinations, is the most productive road to follow. There is an evident need for more sophisticated approaches to this tumor, which has unique metabolic characteristics that should be pharmacologically exploitable. Past experience has indicated that such a setting may permit dramatic therapeutic accomplishment. There is a strong need for animal models or established cell lines which would facilitate preclinical therapeutic exploration. The carcinoid syndrome presents an unparalleled opportunity for fundamental physiologic observations and for experimental therapeutic study that can have applicability not only in palliating the syndrome itself but also in the management of other pathophysiologic states that may involve more subtle abnormalities of the same hormonal mechanisms. The patient with the carcinoid tumor should not just be a fascinating curio for grand rounds exhibition. He should be a focal point for research involving an experienced, multidisciplinary clinical team supported by devoted basic scientists. If our patient resources and efforts can be concentrated in this manner, the carcinoid should be a strong candidate for the next medically curable human cancer.


This article has been cited by other articles:


Home page
JCOHome page
D. G. Haller
The Next 25 Years
J. Clin. Oncol., December 20, 2008; 26(36): 5840 - 5840.
[Full Text] [PDF]


Home page
JCOHome page
L. K. Kvols
Revisiting C.G. Moertel's Land of Small Tumors
J. Clin. Oncol., November 1, 2008; 26(31): 5005 - 5007.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Van Buren II, A. Rashid, A. D. Yang, E. K. Abdalla, M. J. Gray, W. Liu, R. Somcio, F. Fan, E. R. Camp, J. C. Yao, et al.
The Development and Characterization of a Human Midgut Carcinoid Cell Line
Clin. Cancer Res., August 15, 2007; 13(16): 4704 - 4712.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
J. J. Van Gompel, M. Kunnimalaiyaan, K. Holen, and H. Chen
ZM336372, a Raf-1 activator, suppresses growth and neuroendocrine hormone levels in carcinoid tumor cells
Mol. Cancer Ther., June 1, 2005; 4(6): 910 - 917.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
D. J. Kwekkeboom, J. J. Teunissen, W. H. Bakker, P. P. Kooij, W. W. de Herder, R. A. Feelders, C. H. van Eijck, J.-P. Esser, B. L. Kam, and E. P. Krenning
Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors
J. Clin. Oncol., April 20, 2005; 23(12): 2754 - 2762.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
G. A. Kaltsas, G. M. Besser, and A. B. Grossman
The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors
Endocr. Rev., June 1, 2004; 25(3): 458 - 511.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. M. Connolly, H. V. Schaff, C. J. Mullany, M. D. Abel, and P. A. Pellikka
Carcinoid Heart Disease: Impact of Pulmonary Valve Replacement in Right Ventricular Function and Remodeling
Circulation, September 24, 2002; 106(12_suppl_1): I-51 - I-56.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
H. M. Connolly, H. V. Schaff, C. J. Mullany, J. Rubin, M. D. Abel, and P. A. Pellikka
Surgical Management of Left-Sided Carcinoid Heart Disease
Circulation, September 18, 2001; 104(90001): I-36 - 40.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. A. Gilbert, L. M. Frederick, and M. M. Ames
The Aromatic-L-Amino Acid Decarboxylase Inhibitor Carbidopa Is Selectively Cytotoxic to Human Pulmonary Carcinoid and Small Cell Lung Carcinoma Cells
Clin. Cancer Res., November 1, 2000; 6(11): 4365 - 4372.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
K. Öberg
Carcinoid Tumors: Current Concepts in Diagnosis and Treatment
Oncologist, October 1, 1998; 3(5): 339 - 345.
[Abstract] [Full Text]


Home page
Arch Otolaryngol Head Neck SurgHome page
O. Laccourreye, D. Brasnu, F. Carnot, P. Fichaux, and H. Laccourreye
Carcinoid (Neuroendocrine) Tumor of the Arytenoid
Arch Otolaryngol Head Neck Surg, December 1, 1991; 117(12): 1395 - 1399.
[Abstract] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 1983 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online